Jazz Pharmaceuticals, Inc. and its subsidiaries, including Greenwich Biosciences, Inc.
Registered Principal Details
Business Or Interest:
Pharmaceutical manufacturing and healthcare
Lobbying Interests:
All matters affecting the pharmaceutical manufacturing and healthcare industries
CEO Name:
Bruce Cozadd
Designated Agent for Filer
Pharmaceutical manufacturing and healthcare
Lobbying Interests:
All matters affecting the pharmaceutical manufacturing and healthcare industries
CEO Name:
Bruce Cozadd
Designated Agent for Filer
Contact
JUS
Jennie U Skelton
c/o Politicom Law LLP, 28 Liberty Ship Way, Suite 2815
Sausalito, CA 94965
(415) 903-2800
(415) 610-7604
greenwichbio@politicomlaw.com
http://www.jazzpharma.com
c/o Politicom Law LLP, 28 Liberty Ship Way, Suite 2815
Sausalito, CA 94965
(415) 903-2800
(415) 610-7604
greenwichbio@politicomlaw.com
http://www.jazzpharma.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Administrative Rulemaking Proceedings
Agency Name
Controlled Substances Board (CSB)
Subject
Scheduling of FDA approved cannabidiol drugs
Scope Statement
SS 121_18
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Controlled Substances Board (CSB)
Subject
Scheduling of FDA approved cannabidiol drugs
Scope Statement
SS 121_18
For
Notification Date5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Topics Not Yet Assigned A Bill Or Rule Number
Any legislation or rule that impacts access to Epidolex or its successor name, or cannabinol in a drug product approved by the United States Food and Drug Administration
Development, drafting or introduction of a proposal relating to
Any legislation or rule that impacts access to Epidolex or its successor name, or cannabinol in a drug product approved by the United States Food and Drug Administration
Any legislation or rule that impacts access to Epidolex or its successor name, or cannabinol in a drug product approved by the United States Food and Drug Administration
Action Intended To Affect
Both Legislative matter and rule
Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
all matters affecting the regulation and reimbursement of CBD products and the effects on consumers
all matters affecting the regulation and reimbursement of CBD products and the effects on consumers
Action Intended To Affect
Both Legislative matter and rule
Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
5/24/2021
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2021 January - June |
2021 July - December |
2022 January - June |
2022 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2021 January - June $27,000.00 |
2021 July - December $27,000.00 |
2022 January - June $27,000.00 |
2022 July - December $0.00 |
Total $81,000.00 |
| Total Hours Communicating | 2021 January - June 1.25 |
2021 July - December 0.00 |
2022 January - June 0.00 |
2022 July - December 1.00 |
Total 2.25 |
| Total Hours Other | 2021 January - June 4.00 |
2021 July - December 3.00 |
2022 January - June 2.00 |
2022 July - December 6.00 |
Total 15.00 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
No legislative bills/resolutions found.
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2021 January - June |
2021 July - December |
2022 January - June |
2022 July - December |
Total |
|---|---|---|---|---|
| 2021 January - June 40% |
2021 July - December 10% |
2022 January - June 10% |
2022 July - December |
Total 15% |
Minor Efforts
No minor efforts found.
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication